entertainment -WSS

entertainment

author：hotspot 2025-10-01 21:40:02 - browse：61582

STAT

What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how do you pronounce “Bayer”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Live from Boston at the 2023 STAT Summit, we discuss the latest news in the life sciences, including a milestone in genome editing, a twist in the search for ALS treatments, and the polarizing process of saying words in biotech.

For more on what we cover, here’s the latest from the Summit; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Eli Lilly expects to double planned employment in Boston center

WSS

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Medicare inequities exacerbate Puerto Rico’s health disparities

STAT Summit: Biotech founders on deal

FDA warns J&J's Abiomed: We will regulate your software

A solution to the after

First Opinion Podcast: Long Covid needs a new approach

Wikipedia

entertainment

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA struggles to regulate food additives, sometimes for decades

BioMarin wins approval for gene therapy to treat hemophilia A

A solution to the after

Walensky prepares to leave CDC — and Congress — behind

Why health workers in Gaza are injured or die at high rates

Continuity nursing helped my family in our darkest PICU moments

New documents shed light on MD Anderson Cancer Institute feud

Supreme Court strikes down use of affirmative action

NIH study of ME/CFS points to clear biological hallmarks

focus

STAT Summit: Biotech founders on deal

STAT Readout Newsletter: Today's biggest biotech updates

Solve the antibiotic resistance crisis with preventive drugs

R1 RCM gets $5.8 billion buyout offer from private equity firm

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

R1 RCM gets $5.8 billion buyout offer from private equity firm

explore

entertainment

leisure time

knowledge